NCT03225872

Brief Summary

Osteosarcoma is very rare cancer of the bone. The investigator started the BOOST registry and biobank to make sure every patient has the opportunity to participate in research.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
362

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2017

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 3, 2017

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

July 19, 2017

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 21, 2017

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 27, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 27, 2020

Completed
Last Updated

December 2, 2025

Status Verified

November 1, 2025

Enrollment Period

3.1 years

First QC Date

July 19, 2017

Last Update Submit

November 24, 2025

Conditions

Osteosarcoma

Keywords

OsteosarcomaBone cancerFamily-based study

Outcome Measures

Primary Outcomes (1)

  • Determine if genes can determine osteosarcoma

    To do this the investigator will compare the genes of people with osteosarcoma to the genes of people who do not have these conditions.

    Baseline

Study Arms (1)

Osteosarcoma patients and family members

Osteosarcoma patients and family members

Eligibility Criteria

Age0 Years+
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Worldwide

You may not qualify if:

  • Does not understand English.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Masonic Cancer Center

Minneapolis, Minnesota, 55455, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

The investigator will collect saliva and if available baby teeth. There will be no cost to you. If the investigator finds out that your sample doesn't have enough cells to be useful, the investigator may call you for an additional sample.

MeSH Terms

Conditions

OsteosarcomaBone Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms, Bone TissueNeoplasms, Connective TissueNeoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasmsSarcomaNeoplasms by SiteBone DiseasesMusculoskeletal Diseases

Study Officials

  • Logan G. Spector, PhD

    University of Minnesota

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
FAMILY BASED
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 19, 2017

First Posted

July 21, 2017

Study Start

January 3, 2017

Primary Completion

January 27, 2020

Study Completion

January 27, 2020

Last Updated

December 2, 2025

Record last verified: 2025-11

Locations

US(1)